



## NOTICE OF APPLICATION SUBMITTAL CITY OF MENLO PARK PLANNING DIVISION

NOTICE IS HEREBY GIVEN that the Planning Division of the City of Menlo Park, California has received a formal application for the following proposal:

Use Permit/Refuge Biotechnologies/1505 Adams Drive, Suite C: Request for a use permit for the use and storage of hazardous materials for the research and development of cell-based treatments for cancer and other diseases within an existing building located in the M-2 (General Industrial) zoning district. All hazardous materials would be used and stored within the building.

The application will require review and action by the Planning Commission at a scheduled public meeting. The date of the public meeting has not yet been determined. Once the proposal is scheduled for a specific meeting date, a second notice will be mailed with specific information on the meeting date, time and place. The second notice will be mailed 15 days prior to the meeting date.

The project file may be viewed by the public on weekdays between the hours of 7:30 a.m. and 5:30 p.m. Monday through Thursday and 8:00 a.m. to 5:00 p.m. on Friday, with alternate Fridays closed, at the Community Development Department, 701 Laurel Street, Menlo Park, California.

Please find attached to this notice, copies of the project plans and site information as submitted by the applicant. City staff has not completed review of the plans and site information as of the date of this notice. As a result of City staff review and public comment, the preliminary plans may be revised prior to any public meeting on this proposal. If you are interested in viewing revised project plans, they will be available for review at the City offices one week prior to the Planning Commission meeting, which will be advertised in the public hearing notice, and attached to the hard copy of the staff report which will be available on the Thursday prior to the meeting.

If you have any comments or questions on this proposal, please call Kyle Perata, Senior Planner, at (650) 330-6721 or email him at [ktperata@menlopark.org](mailto:ktperata@menlopark.org). The Planning Division encourages submittal of comments and questions by December 20, 2016 in order for staff and the applicant to fully consider all comments and questions prior to the preparation of the staff report.

*Si usted necesita más información sobre este proyecto, por favor llame al 650-330-6702, y pregunte por un asistente que hable español.*



Business Summary  
October 2016

At Refuge Biotechnologies Inc, we make cell-based therapies for the treatment of cancer and other serious diseases. We use CRISPR based gene editing technologies to reprogram an individual's immune cells *ex vivo* (*outside the body*) to better recognize and kill cancer cells while also sparing healthy cells. Compared to existing immunotherapy technologies, such as CAR-T (chimeric antigen receptor T-cells), our platform offer unprecedented cell type and tissue specificity. Existing CAR-T therapies often times target both cancerous as well as healthy tissues, leading to severe side effects. Our approach enables the reprogrammed immune cells to make a decision *in vivo* (inside the body) on whether the target cell is cancerous or healthy, thereby significantly reducing the side effects while also boosting potency.

In addition to the treatment of cancer, our approach to reprogramming cells may also potentially enable the treatment of:

Neurodegenerative diseases, such as Alzheimer's Disease

Regenerative medicine for organ failure

Autoimmune diseases, such as Multiple Sclerosis, Lupus, or Crohn's diseases

Refuge Biotechnologies Inc is moving its operations from 515 Olmsted Rd, Stanford CA to this site at 1505 Adams Drive, Menlo Park, CA. The new facility will be the sole location for research, product development and manufacturing. Refuge Biotechnologies Inc currently has 4 employees on-site and expects to grow to as many as 25 employees in Menlo Park over the next five years.

As part of its research and development efforts, Refuge Biotechnologies Inc will use small quantities of some hazardous materials, in the properly equipped labs on site. These materials will be used in fume hoods or other appropriately exhausted space. Small quantities of chemicals such as acids are used in preparing experimental solutions. Other various solvents, including isopropyl alcohol, are used to clean and process our components. The container size for most hazardous substances are 1 gallon containers for bench top use.

Refuge Biotechnologies Inc will not manufacture any materials at the site for the near and mid-future, and will produce hazardous waste on the order of a few gallons per month as a result of its R&D activities.

Neither an air emissions permit nor a wastewater discharge permit is anticipated to be required for the facility.

Chemicals and other reagents will be delivered by common carrier. Delivery frequency will vary with the pace of activities, but is not expected to exceed bi-monthly. Hazardous waste is removed from site by a licensed hauler; removal is generally on a bi-monthly basis.

RECEIVED

OCT 26 2016


CITY OF MENLO PARK  
BUILDING











 <p><b>EXCLUSIVE AGENTS</b> TEL. 650 . 330 . 3600 FAX. 650 . 330 . 3636</p>	<table border="1"> <thead> <tr> <th colspan="2">RENTABLE (DRIP-LINE) SQ. FT.</th> </tr> </thead> <tbody> <tr> <td>1ST FLOOR</td> <td>19,360 S.F.</td> </tr> <tr> <td>2ND FLOOR</td> <td>10,880 S.F.</td> </tr> <tr> <td>ELECTRIC RM.</td> <td>195 S.F.</td> </tr> <tr> <td><b>TOTAL</b></td> <td><b>30,240 S.F.</b></td> </tr> </tbody> </table>	RENTABLE (DRIP-LINE) SQ. FT.		1ST FLOOR	19,360 S.F.	2ND FLOOR	10,880 S.F.	ELECTRIC RM.	195 S.F.	<b>TOTAL</b>	<b>30,240 S.F.</b>	<p align="center"><b>SECOND FLOOR PLAN</b> REFUGE BIOTECHNOLOGIES</p> <hr/> <p align="center">GEI 10/16</p>	 <p align="center"><b>BUILDING 16</b> 1505 ADAMS DRIVE, MENLO PARK</p>
RENTABLE (DRIP-LINE) SQ. FT.													
1ST FLOOR	19,360 S.F.												
2ND FLOOR	10,880 S.F.												
ELECTRIC RM.	195 S.F.												
<b>TOTAL</b>	<b>30,240 S.F.</b>												